Skip to main content
The UC Berkeley Center for the Science of Psychedelics will investigate cognition, perception and emotion, as well as their biological bases in the brain, through the use of psychedelics, including psilocybin.
The use of MDMA-assisted psychotherapy for the treatment of PTSD could receive final approval by the FDA by 2022, Rick Doblin, PhD, of the Multidisciplinary Association for Psychedelic Studies told Psych Congress 2020 preconference attendees.
BLOG: Psychedelic-assisted therapies, once consigned to the fringes of psychiatric practice, are exploding into the mainstream of psychiatry and will take center stage at a Psych Congress preconference.
MindMed and the University Hospital Basel’s Liechti Lab announced plans for a Phase 1 clinical trial in which LSD and MDMA will be paired within a single session to evaluate the potential for reducing negative effects in psychedelic-assisted therapy.
Unlimited Sciences, a not-for-profit research organization based in Denver, and the Johns Hopkins University Center for Psychedelic and Consciousness Research announced they are collaborating on a study of real-world uses and effects of psychedelic mushrooms (Psilocybin).
Back to Top